Drug intelligence / Profile preview

PES200

Development stage: Preclinical
Lead developer: Virpax Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

PES200 is an intranasal drug candidate developed by Virpax Pharmaceuticals. It utilizes Molecular Envelope Technology (MET), a nanotechnology-based delivery system, and is being developed to manage post-traumatic stress disorder (PTSD). This technology is designed to enable nose-to-brain transport, bypassing the blood-brain barrier for central nervous system (CNS)-targeted drugs.

Targets

DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on PES200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PES200.

Explore the full profile